Jesse A Berlin

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. pmc Consensus-based recommendations for investigating clinical heterogeneity in systematic reviews
    Joel J Gagnier
    Department of Orthopaedic Surgery, University of Michigan, MedSport, 24 Frank Lloyd Wright Drive, Ann Arbor, MI 48106, USA
    BMC Med Res Methodol 13:106. 2013
  2. doi request reprint Meta-analysis of clinical trial safety data in a drug development program: answers to frequently asked questions
    Jesse A Berlin
    Janssen Research and Development, Titusville, NJ 08560, USA
    Clin Trials 10:20-31. 2013
  3. doi request reprint Some methodological points to consider when performing systematic reviews in comparative effectiveness research
    Jesse A Berlin
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ 08560, USA
    Clin Trials 9:27-34. 2012
  4. pmc Genome-wide association study for empirically derived metabolic phenotypes in the Framingham Heart Study offspring cohort
    Marsha Wilcox
    Epidemiology, Johnson and Johnson Pharmaceutical Research and Development, LLC, 1125 Trenton Harbourton Road, PO Box 200, M S K304, Titusville, New Jersey 08560 USA
    BMC Proc 3:S53. 2009
  5. pmc Comparison of methods for correcting population stratification in a genome-wide association study of rheumatoid arthritis: principal-component analysis versus multidimensional scaling
    Dai Wang
    Department of Pharmacogenomics, Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08869 USA
    BMC Proc 3:S109. 2009
  6. doi request reprint N-of-1 clinical trials should be incorporated into clinical practice
    Jesse A Berlin
    Johnson and Johnson Pharmaceutical Research and Development, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USA
    J Clin Epidemiol 63:1283-4. 2010
  7. pmc Inclusion of women in clinical trials
    Jesse A Berlin
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ, USA
    BMC Med 7:56. 2009
  8. pmc Why industry should register and disclose results of clinical studies--perspective of a recovering academic
    Jesse A Berlin
    Johnson and Johnson Pharmaceutical Research and Development, LLC, 1125 Trenton Harbourton Road, PO Box 200, Titusville, NJ 08560, USA
    BMJ 330:959. 2005
  9. pmc Adverse event detection in drug development: recommendations and obligations beyond phase 3
    Jesse A Berlin
    Johnson and Johnson Pharmaceutical Research and Development, 1125 Trenton Harbourton Rd, PO Box 200, Mail Stop K 304, Titusville, NJ 08560, USA
    Am J Public Health 98:1366-71. 2008
  10. doi request reprint Use of adjectives in abstracts when reporting results of randomized, controlled trials from industry and academia
    M Soledad Cepeda
    Janssen Research and Development, LLC, 1125 Trenton Harbourton Road, Titusville, NJ, 08560, USA
    Drugs R D 15:85-139. 2015

Collaborators

Detail Information

Publications11

  1. pmc Consensus-based recommendations for investigating clinical heterogeneity in systematic reviews
    Joel J Gagnier
    Department of Orthopaedic Surgery, University of Michigan, MedSport, 24 Frank Lloyd Wright Drive, Ann Arbor, MI 48106, USA
    BMC Med Res Methodol 13:106. 2013
    ..The objective of this project was to develop recommendations for investigating clinical heterogeneity in systematic reviews...
  2. doi request reprint Meta-analysis of clinical trial safety data in a drug development program: answers to frequently asked questions
    Jesse A Berlin
    Janssen Research and Development, Titusville, NJ 08560, USA
    Clin Trials 10:20-31. 2013
    ..Once a product is marketed, sponsors add postapproval clinical trial data to the body of information to help understand existing safety concerns or those that arise from other postapproval data sources, such as spontaneous reports...
  3. doi request reprint Some methodological points to consider when performing systematic reviews in comparative effectiveness research
    Jesse A Berlin
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ 08560, USA
    Clin Trials 9:27-34. 2012
    ..There is an ongoing discussion as to what types of evidence are appropriate to inform CER and how best to interpret various forms of evidence...
  4. pmc Genome-wide association study for empirically derived metabolic phenotypes in the Framingham Heart Study offspring cohort
    Marsha Wilcox
    Epidemiology, Johnson and Johnson Pharmaceutical Research and Development, LLC, 1125 Trenton Harbourton Road, PO Box 200, M S K304, Titusville, New Jersey 08560 USA
    BMC Proc 3:S53. 2009
    ..The directional findings will provide the basis for hypothesis generation for syndromes such as the metabolic syndrome and obesity...
  5. pmc Comparison of methods for correcting population stratification in a genome-wide association study of rheumatoid arthritis: principal-component analysis versus multidimensional scaling
    Dai Wang
    Department of Pharmacogenomics, Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08869 USA
    BMC Proc 3:S109. 2009
    ....
  6. doi request reprint N-of-1 clinical trials should be incorporated into clinical practice
    Jesse A Berlin
    Johnson and Johnson Pharmaceutical Research and Development, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USA
    J Clin Epidemiol 63:1283-4. 2010
    ..Incorporating these studies into clinical practice will require creative thinking so as to maintain rigor without excessive disruption of routine care...
  7. pmc Inclusion of women in clinical trials
    Jesse A Berlin
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ, USA
    BMC Med 7:56. 2009
    ....
  8. pmc Why industry should register and disclose results of clinical studies--perspective of a recovering academic
    Jesse A Berlin
    Johnson and Johnson Pharmaceutical Research and Development, LLC, 1125 Trenton Harbourton Road, PO Box 200, Titusville, NJ 08560, USA
    BMJ 330:959. 2005
  9. pmc Adverse event detection in drug development: recommendations and obligations beyond phase 3
    Jesse A Berlin
    Johnson and Johnson Pharmaceutical Research and Development, 1125 Trenton Harbourton Rd, PO Box 200, Mail Stop K 304, Titusville, NJ 08560, USA
    Am J Public Health 98:1366-71. 2008
    ..More work is needed in analysis of data from spontaneous reports of adverse effects and automated databases, design of ad hoc studies, and design of economically feasible large randomized studies...
  10. doi request reprint Use of adjectives in abstracts when reporting results of randomized, controlled trials from industry and academia
    M Soledad Cepeda
    Janssen Research and Development, LLC, 1125 Trenton Harbourton Road, Titusville, NJ, 08560, USA
    Drugs R D 15:85-139. 2015
    ..The language used to describe results could affect perceptions of the efficacy or safety of interventions. We sought to compare the adjectives used in clinical trial reports of industry-authored and non-industry-authored research...
  11. doi request reprint Use of ClinicalTrials.gov to estimate condition-specific nocebo effects and other factors affecting outcomes of analgesic trials
    M Soledad Cepeda
    Janssen Pharmaceutical Research and Development, LLC, Titusville, NJ 08560, USA
    J Pain 14:405-11. 2013
    ..Attrition rates differ across pain conditions. Migraine studies had the lowest withdrawal rate. Tools like Sherlock facilitate conducting research in the ClinicalTrials.gov registry...